Clinical Trial Update: ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring ABI-007 (nab-paclitaxel) in combination with Bevacizumab for recurrent or metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ABI-007 (nab-paclitaxel)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Premiere Oncology | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN